AorTech has raised a gross total of £2.6m to fund two new projects. As a licensing and royalty business of its patented Elast-Eon technology, AorTech has been marginally EBITDA positive. We believe there is substantial potential share price upside as, in our view, each of the new projects could create £50m of shareholder value. Textiles (patches and grafts) should have initial sales within two years while heart valves will potentially progress to a licensing stage in a similar tim
12 Jun 2018
New projects to drive shareholder value
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New projects to drive shareholder value
RUA Life Sciences Plc (RUA:LON) | 10.8 0 0.0% | Mkt Cap: 6.67m
- Published:
12 Jun 2018 -
Author:
Robert Sanders -
Pages:
20
AorTech has raised a gross total of £2.6m to fund two new projects. As a licensing and royalty business of its patented Elast-Eon technology, AorTech has been marginally EBITDA positive. We believe there is substantial potential share price upside as, in our view, each of the new projects could create £50m of shareholder value. Textiles (patches and grafts) should have initial sales within two years while heart valves will potentially progress to a licensing stage in a similar tim